Cytek Biosciences, Inc. (CTKB)
NASDAQ:CTKB
Want to see CTKB full AI Analyst Report?
Top Page
Cytek Biosciences
(NASDAQ:CTKB)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.00
▼(-13.23% Downside)
Action:Reiterated
Date:06/17/26
The score is held back primarily by weak financial performance (large losses and recent cash burn) and a bearish technical setup (below key moving averages with negative MACD). The latest earnings call provides a partial offset via reaffirmed guidance, recurring revenue momentum, and an expected path to positive adjusted EBITDA in 2026, but near-term margin and expense pressures remain.
Positive Factors
Recurring revenue momentum
Growth in reagents and service revenues increases recurring, higher-margin streams that smooth cyclicality from capital instrument sales. A rising installed-base driven recurring mix supports predictable cash inflows, improves lifetime customer value, and underpins long-term margin improvement as installed units scale.
Negative Factors
Deteriorating profitability
Material margin compression and the return to large net losses indicate the core business isn't yet delivering profitable unit economics. Sustained negative returns undermine reinvestment capacity, raise the need for margin remediation or structural changes, and lengthen the timeline to self-sustaining profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue momentum
Growth in reagents and service revenues increases recurring, higher-margin streams that smooth cyclicality from capital instrument sales. A rising installed-base driven recurring mix supports predictable cash inflows, improves lifetime customer value, and underpins long-term margin improvement as installed units scale.
Read all positive factors
Cytek Biosciences (CTKB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$498.49M
Dividend YieldN/A
Average Volume (3M)1.83M
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth3.61%
EPS Growth-568.29%
CountryUS
Employees663
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.57
Shares Outstanding129,142,600
10 Day Avg. Volume3,347,127
30 Day Avg. Volume1,833,508
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.89
Price to Sales (P/S)3.20
P/FCF Ratio-73.56
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.37
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda-21.88
Forecast
1Y Price Target
$5.69Price Target Upside23.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$208.83M
Cytek Biosciences Business Overview & Revenue Model
Company Description
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Light...
How the Company Makes Money
Cytek makes money primarily by selling flow cytometry instruments and then generating recurring follow-on revenue from the installed base through consumables and services. Key revenue streams typically include: (1) Instrument sales: upfront revenu...
Cytek Biosciences Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call presented a mix of constructive commercial momentum—led by a strong U.S. rebound, double-digit growth in recurring revenue, robust installed base expansion and growing cloud/user engagement—while also disclosing near-term profitability pressures from higher operating and legal expenses, regional disruption (EMEA) and APAC order timing. Management reaffirmed full-year guidance and expects adjusted EBITDA to turn positive for 2026, supported by a strong balance sheet.Positive Updates
Revenue Growth and Constructive Start to 2026
Q1 2026 revenue was $44.1M, up 6% year-over-year from $41.5M, representing a constructive start to the year and management's view of a return to more normal U.S. market conditions.
Negative Updates
Regional Headwinds in EMEA
EMEA revenue declined 7% year-over-year to $10.8M; management attributed softness to disruption from the conflict in the Middle East and an end-of-quarter shipment delay in another region.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth and Constructive Start to 2026
Q1 2026 revenue was $44.1M, up 6% year-over-year from $41.5M, representing a constructive start to the year and management's view of a return to more normal U.S. market conditions.
Read all positive updates
Company Guidance
Cytek reaffirmed full‑year 2026 revenue guidance of $205–$212 million (about 2%–5% growth year‑over‑year) assuming no change in currency rates, saying the outlook rests on continued growth in services and reagents at recent levels, flat‑to‑modest instrument growth and a contingency for macro risks; Q1 metrics cited include GAAP gross margin of 48% (adjusted gross margin 51%), an adjusted EBITDA loss of $9.1M (management expects adjusted EBITDA to improve each quarter and to be positive for full‑year 2026), trailing‑12‑month recurring revenue of $18.4M (35% of total, +19% YoY), and cash and marketable securities of $262.2M as of March 31, 2026, with the company forecasting gross margins to increase as revenue builds seasonally.Cytek Biosciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 204.17M | 201.49M | 200.45M | 193.01M | 164.04M | 127.95M |
| Gross Profit | 105.56M | 104.46M | 111.11M | 109.43M | 100.97M | 79.14M |
| EBITDA | -22.15M | -17.39M | 4.79M | -4.41M | 9.49M | 8.92M |
| Net Income | -74.00M | -66.54M | -6.02M | -12.15M | 2.58M | 3.00M |
Balance Sheet | ||||||
| Total Assets | 449.11M | 461.54M | 499.50M | 494.46M | 519.48M | 463.31M |
| Cash, Cash Equivalents and Short-Term Investments | 262.23M | 261.53M | 277.86M | 262.41M | 341.15M | 364.62M |
| Total Debt | 36.33M | 23.74M | 17.02M | 14.14M | 18.09M | 0.00 |
| Total Liabilities | 121.47M | 119.80M | 103.76M | 101.39M | 93.93M | 57.92M |
| Stockholders Equity | 327.64M | 341.74M | 395.74M | 393.06M | 425.30M | 405.04M |
Cash Flow | ||||||
| Free Cash Flow | -12.70M | -8.77M | 21.85M | 454.00K | -22.10M | 266.00K |
| Operating Cash Flow | -7.30M | -4.69M | 25.38M | 5.28M | -12.23M | 4.63M |
| Investing Cash Flow | -26.41M | 10.12M | -82.97M | -93.89M | -55.91M | -20.99M |
| Financing Cash Flow | 2.09M | -13.43M | -15.82M | -41.81M | 5.51M | 213.56M |
Cytek Biosciences Technical Analysis
Neutral
4.61
Price Trends
4.21
Negative
4.33
Negative
4.48
Negative
Market Momentum
-0.06
Negative
50.49
Neutral
40.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTKB, the sentiment is Neutral. The current price of 4.61 is above the 20-day moving average (MA) of 4.05, above the 50-day MA of 4.21, and above the 200-day MA of 4.48, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 50.49 is Neutral, neither overbought nor oversold. The STOCH value of 40.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTKB.
Cytek Biosciences Risk Analysis
Cytek Biosciences disclosed 73 risk factors in its most recent earnings report. Cytek Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cytek Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.90B | -25.99 | -36.79% | ― | 20.20% | -0.81% | |
67 Neutral | $734.27M | 21.94 | 16.27% | ― | 1.52% | ― | |
62 Neutral | $701.61M | -41.12 | -9.56% | ― | 16.77% | 39.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $409.99M | -3.05 | -488.45% | ― | 5.04% | 81.29% | |
49 Neutral | $498.49M | -7.05 | -20.77% | ― | 3.61% | -568.29% | |
47 Neutral | $437.84M | -5.27 | -17.61% | ― | 3.63% | -93.57% |
* Healthcare Sector Average
CTKB
Cytek Biosciences
4.07
0.84
26.01%
PACB
Pacific Biosciences
1.31
0.11
9.17%
VREX
Varex Imaging
10.52
2.57
32.33%
SIBN
SI-Bone
15.95
-1.88
-10.54%
BFLY
Butterfly Network
7.67
5.66
281.59%
BVS
Bioventus
9.29
2.53
37.43%
Cytek Biosciences Corporate Events
Executive/Board ChangesShareholder Meetings
Cytek Biosciences Stockholders Back Board, Pay and Auditor
Positive
Jun 16, 2026
On June 10, 2026, Cytek Biosciences, Inc. held its 2026 annual meeting of stockholders, with approximately 86.1% of outstanding common shares represented, reflecting strong investor engagement in the company’s corporate governance. Stockhold...
Executive/Board Changes
Cytek Biosciences Announces Resignation of Senior Sales Executive
Neutral
Jun 2, 2026
On May 27, 2026, Cytek Biosciences, Inc. announced that Philippe Busque, Ph.D., submitted his resignation as Senior Vice President, Global Sales and Services, effective June 5, 2026. The departure, which the company said is to allow him to pursue ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.